Biotechnology
Viva Biotech's Recent Conferences & Events Review
HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...
2023-05-05 19:58
4037
Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary
SEATTLE, May 5, 2023 /PRNewswire/ -- Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias Technology (TibTech), its accredited lab for cancer screening and in vitro diagnostics, at the Hong Kong Science and Tech...
2023-05-05 15:00
1825
P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'
* Dons the purple ribbon for the 2nd consecutive year to raise awareness on Peripheral Neuropathy, a condition significantly underdiagnosed and undertreated inAsia, Middle East & Africa * Releases new research study highlighting the role of B Vitamins in supporting healthy nerve functions SIN...
2023-05-05 11:30
3739
MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA
GENEVA, May 5, 2023 /PRNewswire/ -- The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr.Arthur Lee at the Cardiac & Vascular Institute inFlorida. This study evaluates SELUTION SLR™ in the treatment of occlusive disease of the superficial femoral artery (SFA) and p...
2023-05-05 08:00
3335
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the pot...
2023-05-05 08:00
2001
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ -- ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient wa...
2023-05-05 01:00
2542
SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
* SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistantE. coli, which can cause fatal infections in vulnerable hematological cancer patients * SNIPR001 represents the first CRISPR- therapeutic developed to specifically removeE. coli in the ...
2023-05-05 00:52
2661
ANGUS ANNOUNCES CORPORATE REBRANDING, WILL CHANGE NAME TO "ADVANCION"
New name and brand reflect Company's strategic transformation into a leading global producer of specialty ingredients for Life Sciences, Personal Care and other essential markets BUFFALO GROVE, Ill., May 4, 2023 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company") today unveiled a new n...
2023-05-04 21:00
3607
Cambridge Infinitus Research Centre Launches World Leading AI-based Technology Platform ERnet for Studies of Cellular Health
GUANGZHOU, China, May 4, 2023 /PRNewswire/ -- The Cambridge Infinitus Research Centre (CIRCE) was officially established in 2015 as Infinitus' first international scientific research collaboration platform outside ofChina. CIRCE recently achieved another scientific and technological breakthrough ...
2023-05-04 16:00
2896
European Wellness Joint Research with Heidelberg University in Journal Publication
HEIDELBERG, Germany, May 4, 2023 /PRNewswire/ -- European Wellness Academy (EWA), a wholly owned subsidiary European Wellness Biomedical Group (EW Group) has entered into a cooperation agreement with Heidelberg University in medical research. The research project, titled "A Tendon Specific Double...
2023-05-04 13:39
2400
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 3, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for infl...
2023-05-03 22:43
3225
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ s...
2023-05-03 21:00
2184
LenioBio GmbH Announces New CEO
DUSSELDORF, Germany, May 3, 2023 /PRNewswire/ -- LenioBio GmbH, the Düsseldorf-based cell-free protein expression company, has announced that its founder and CEO, Dr.Remberto Martis, will be stepping down as CEO and has proudly named his successor as André Goerke, startingJune 1st, 2023. Andr...
2023-05-03 20:00
2720
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
SHANGHAI, May 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy...
2023-05-03 12:00
1976
Merck Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South Korea
* MoU with Merck's Life Science business aimed at supporting the region's healthcare ecosystem * Proposed bioprocessing facility to be based in Daejeon City * Further collaboration aims to support emerging biotech companies and academic research DAEJEON CITY, South Korea, May 3, 2023 /PRNe...
2023-05-03 10:00
3376
Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients
SUZHOU, China, May 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the enrollment of ...
2023-05-03 08:00
3840
Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis
* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...
2023-05-03 00:07
2025
Cytiva and Pall Life Sciences complete integration to create a global innovation and solutions leader in biotechnology
* Combined broad and differentiated portfolio with trusted technologies and commercial and service organizations * Customers will have simpler and greater access to industry-leading expertise, tools, and services AMERSHAM, United Kingdom, May 2, 2023 /PRNewswire/ -- Cytiva and the life scienc...
2023-05-02 12:01
3539
Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease
TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an
Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel
MagicTouch
2023-05-01 18:30
2855
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...
2023-05-01 08:58
2701
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714